Loading patent…
AssigneesUniversity of Maryland, The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsSiba K. Samal, Peter L. Collins
Estimating the term…
The present invention concerns cDNAs for making attentuated, infectious Newcastle disease virus (NDV). Another aspect of the invention relates to methods of making the cDNAs. Another aspect of the invention is a vector containing the cDNA optionally linked to an operable promoter. Within the scope of the invention are vaccines comprising the attenuated, infectious NDV. Also disclosed are methods of making the vaccines and methods of using the vaccines to prevent or treat Newcastle disease in an avian host. The present invention also concerns the nucleotide sequences of the entire genome of NDV, the leading region, the trailing region, and the NP region, as well as proteins encoded by these nucleotide sequences.
A vaccine for Newcastle disease comprising a genetically engineered live attenuated Newcastle disease virus, wherein the genetically engineered live attenuated Newcastle disease virus has a Fo protein cleavage site having at least two less basic amino acid residues than a Fo protein cleavage site of Newcastle disease virus wild type strain Beaudette C, wherein codons of non-basic amino acid residues replacing the at least two basic amino acid residues are different from codons of the basic amino acid residues by at least two nucleotides;
Dependencies are inferred from the claim text.